DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Rosuvastatin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca's branded Rosuvastatin is Crestor.
After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.
Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China's Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.
It is expected that as more Chinese people suffer from hyperlipidemia, China's Rosuvastatin market will continue to grow in the next few years.
Key Topics Covered:
1 Relevant Concepts of Rosuvastatin
2 Sales of Rosuvastatin in China, 2013-2017
3 Analysis on Major Rosuvastatin Manufacturers in China, 2013-2017
4 Prices of Rosuvastatin in China, 2017-2018
5 Prospect of China's Rosuvastatin Market, 2018-2022
- IPR Pharmaceuticals Inc. (Astrazeneca)
- Lunan Better Pharmaceutical Co. Ltd.
- Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd.
- Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.
- Shionogi & Co. Ltd.
- Zhejiang Jingxin Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/jfqrmd/investigation?w=4